InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Raises Approximately $5.6 Million in PIPE Financing
October 6, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced an approximately $5.6 million private investment in public equity (“PIPE”) financing through the issuance of 4,843,300 common shares at $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price. The financing includes an additional $1 million investment from existing significant shareholder John Paul DeJoria and does […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Telomir-Zn Improvements in Visual Function and Retinal Structure in AMD Model
September 17, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced the peer-reviewed publication of preclinical research showing Telomir-Zn significantly improved visual function, restored retinal structure and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (“AMD”). The study also found treatment was associated with restoration of […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Telomir-Zn Growth Inhibition Across Human and Canine Osteosarcoma Models
September 14, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Telomir-Zn Data Supporting Phase 1/2 TNBC Program
August 10, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data showing Telomir-Zn suppressed tumor growth in prostate and triple-negative breast cancer (“TNBC”) models through selective modulation of intracellular iron and copper. Published in the Journal of Oncology Research and Therapy, the study showed Telomir-Zn inhibited histone demethylases by depleting intracellular iron, selectively killed iron-dependent TNBC cells while sparing […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model
June 15, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. According to the study, treatment produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
May 20, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced publication of peer-reviewed preclinical data in Advances in Redox Research showing that Telomir-Zn delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model, including reduced oxidative stress, lower hepatic copper burden and improved liver function markers. The findings support the biological activity of Telomir-Zn in Wilson’s disease […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. The clearance enables initiation of a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity, supported by […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1
April 24, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., establishing the company as the sole global rights holder of Telomir-1 (Telomir-Zn) and eliminating prior geographic fragmentation of the asset. The transaction, approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
March 31, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced the submission of an Investigational New Drug application to the FDA for Telomir-1 (Telomir-Zn) targeting advanced and metastatic triple-negative breast cancer, supported by preclinical efficacy and safety data demonstrating tumor growth reduction and favorable tolerability. Pending IND clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating the […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models
February 17, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn
February 5, 2026
Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-active ferrous iron in living cells. The company said the findings extend its previously reported iron-reduction data by demonstrating, for the first time, a coupled […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study
January 5, 2026
Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of disease, announced positive results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft models of triple-negative breast cancer conducted in collaboration with BioReperia using its ZTX(R) ONCOLEADS platform. In an aggressive TNBC model with limited responsiveness to paclitaxel, Telomir-1 […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
December 18, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1 (Zn-Telomir), reporting no treatment-related adverse or dose-limiting toxicities across cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models. The preclinical-stage biotechnology company said Telomir-1 was […]
ROTH to Host 14th Annual Technology Conference at the Hard Rock Hotel in New York City
November 12, 2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — via IBN — Roth Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 14th Annual Roth Technology Conference on November 18-19, 2025, at the Hard Rock Hotel, 159 W 48th St, New York, NY 10036. The conference will provide pre-qualified institutional investors with the opportunity to […]
Datavault AI to Showcase Revolutionary Joke Token Technology for Comedic Copyright Protection at Exclusive October 11 Event in Babylon, NY
October 9, 2025
BEAVERTON, Ore., Oct. 09, 2025 (GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (Nasdaq: DVLT), a leader in secure data tokenization and Web 3.0 innovations, today announced it has developed its groundbreaking Joke Token® technology for launch in its first, real-world project. The Company’s Joke Token solution is designed to safeguard comedic content and copyrights. […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success for Telomir-1 in Progeria Cell Lines
June 18, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data demonstrating that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. In studies conducted by Smart Assays, Telomir-1 improved cell viability, reduced oxidative stress, and restored mitochondrial function in cells from a child with Hutchinson-Gilford Progeria Syndrome (HGPS), […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
June 11, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing its lead candidate, Telomir-1, significantly reversed neurological, liver, and kidney symptoms in a genetic animal model of Wilson’s disease, a rare disorder caused by copper accumulation. In zebrafish mimicking human pathology, Telomir-1 delivered a 4- to 5-fold reduction in tremors, normalized movement behaviors, cut liver copper […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough in Age-Reversal Model With Telomir-1
June 5, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical results showing that its lead candidate, Telomir-1, significantly reverses multiple aging markers in a zebrafish model of Werner Syndrome, a rare disorder mimicking accelerated human aging. The orally administered compound extended telomere length by threefold, restored muscle mass and body weight, reduced oxidative stress, and reversed age-related DNA […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) to Pursue Partnerships at BIO 2025 as IND Prep for Telomir-1 Advances
June 2, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, where it will engage in BIO One-on-One Partnering™ to explore licensing, M&A, and strategic collaborations. The company is preparing to submit an IND application by year-end for its lead candidate, Telomir-1, a small molecule designed to […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Vision Restoration and Retinal Regeneration in Preclinical AMD Study
May 29, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating that its oral therapeutic candidate, Telomir-1, restored vision and reversed retinal degeneration in a genetically modified zebrafish model of age-related macular degeneration (“AMD”). In a 14-day study, Telomir-1 improved central vision response, restored retinal architecture across multiple critical layers, reduced oxidative stress by up to 50%, […]
InvestorNewsBreaks – Traders Fair Philippines 2025 to Unite Global Financial Minds in Manila
May 21, 2025
Traders Fair Philippines, the region’s premier financial event, returns to Manila on May 24, 2025, at Edsa Shangri-La for a full-day of education, networking, and market insights. Organized by iEvents, the fair will bring together traders, investors, brokers, and financial service providers for a dynamic showcase of industry trends across forex, cryptocurrency, stocks, futures, and […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline
May 21, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced a $3 million equity investment from The Bayshore Trust, the company’s largest shareholder, through the purchase of 1 million restricted shares at $3.00 each—an 18% premium to the stock’s prior closing price. The raise brings total equity investment from affiliated entities to $4 million, complemented by an undrawn $5 million […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Silver(II) Antimicrobial Drug Candidate Telomir-Ag2
May 15, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced the identification of Telomir-Ag2, a stabilized Silver(II) complex demonstrating potent, broad-spectrum antimicrobial activity, including against drug-resistant MARSA. Developed using the company’s proprietary Telomir-1 platform, Telomir-Ag2 is the first Silver(II) compound to achieve biological compatibility, outperforming its Silver(I) predecessor in preclinical studies. Designed for use in high-risk infections such as burns […]
InvestorNewsBreaks – Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH) Engages Norda Stelo for Gap Analysis at Lac Pelletier, Eyes Near-Term Production
May 7, 2025
Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA:9NH) has engaged Norda Stelo to conduct a Gap Analysis Study for its Lac Pelletier Gold Project in Quebec, marking a critical step toward the potential launch of its exploitation phase. The mandate includes a full review of environmental permitting and identification of regulatory requirements ahead of mining activity. […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Data Supporting Expansion into Autism and Rare Neurological Disorders
May 7, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) has released new preclinical data showing its lead oral candidate, Telomir-1, reverses key markers of cellular decline in human cell lines, including improved mitochondrial activity, reduced oxidative stress, and restored calcium balance. The findings underpin Telomir’s expansion into autism spectrum disorder (ASD) and spasmodic dysphonia (SD), both of which share biological […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success of Telomir-1 in Prostate Cancer Model
March 19, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced preclinical findings showing that its telomere-elongating drug, Telomir-1, reduced tumor size by approximately 50% in a prostate cancer animal model. The study demonstrated that Telomir-1 actively suppresses cancer growth while protecting against chemotherapy-induced toxicity when combined with Paclitaxel. Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 selectively benefited […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success in Age-Reversal Science with Telomir-1
February 26, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical findings demonstrating that its proprietary compound, Telomir-1, fully reverses calcium dysregulation—a key driver of cell death, aging, and disease progression. The study confirmed that Telomir-1 restores calcium homeostasis, reduces oxidative stress, and protects mitochondrial function in multiple human cell lines. The compound showed promise in preventing cellular damage […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Stabilizes Silver(II) for Advanced Medical Applications
February 21, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced a breakthrough with its Telomir-1 platform, successfully stabilizing both Silver(I) (Ag⁺) and highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This advancement overcomes longstanding stability challenges, paving the way for enhanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings. With the silver-based medical market projected to reach billions […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results for Age-Related Macular Degeneration
February 18, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced reactive oxygen species (ROS) induced by copper and iron exposure in human retinal cell lines. The findings suggest Telomir-1’s potential as a disease-modifying therapy for age-related macular degeneration (AMD) by targeting oxidative stress, a key driver of retinal degeneration. The […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Findings for Age-Reversal Therapy
January 7, 2025
Telomir Pharmaceuticals (NASDAQ: TELO), an emerging leader in age-reversal science, announced significant findings from a preclinical progeria lifespan study in collaboration with Nagi Bioscience SA. Using C. elegans nematode models with wrn-1 gene mutations (analogous to human Werner Syndrome), the study demonstrated that Telomir-1 restored lifespan and normalized aging effects, including improved movement velocity and […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
December 23, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) announced promising preclinical findings demonstrating the copper-binding capabilities of its Telomir-1 drug candidate, positioning it as a potential treatment for Wilson’s disease and other copper-related disorders. Recent studies highlighted Telomir-1’s ability to selectively bind and regulate copper, iron, and zinc, providing a foundation for addressing Wilson’s disease, a rare genetic condition […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
December 12, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
December 3, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) announced preclinical findings showcasing the transformative potential of its molecule, Telomir-1, in reversing key parameters of Type 2 diabetes. The study demonstrated significant reductions in fasting glucose levels, improvements in glucose homeostasis, and near pre-diabetic levels of insulin resistance, supported by reduced HOMA-IR values and increased survival rates. Telomir-1’s novel mechanism […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
November 21, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) announced promising preclinical results for Telomir-1, a compound designed to reverse biological aging and enhance longevity. In collaboration with Nagi Biosciences, the study utilized advanced microfluidic technology to test Telomir-1 on aging model organisms, demonstrating increased lifespan, improved mobility, and measurable reversal of age-related decline. These findings highlight Telomir-1’s potential in […]
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
September 27, 2024
Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, will be spotlighted during the upcoming episode of “Health Uncensored with Dr. Drew.” The show will be broadcast on Fox Business Network at 5:30 p.m. EST on Sept. 29, 2024. Dr. Drew will talk […]
InvestorNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
September 4, 2024
Telomir Pharmaceuticals (NASDAQ: TELO), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, today announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel’s extensive career in pharmaceutical innovation spans over 40 years, during which he has been instrumental in the research, development, and regulatory […]
Top 10 Reasons to Attend Blockchain Futurist Conference
April 25, 2024
We feel compelled to tell you just 10 reasons (there are lots more) why Blockchain Futurist Conference 2024 is the years’ must-attend web3 event. “By far the BEST conference that I have ever been to in my life!” Jonathan P. With a huge web3 community, Canada is a fast-growing global hub for blockchain and crypto. […]
InvestorNewsBreaks – Telo Genomics Corp. (TSX.V: TELO) (OTCQB: TDSGF) Notes Key Milestone with Award of College of American Pathologists Accreditation
April 10, 2024
Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry’s leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of […]
ROTH to Host 36th Annual Conference March 17-19 in Dana Point, California
March 11, 2024
NEWPORT BEACH, Calif., March 11, 2024 (GLOBE NEWSWIRE) — via IBN – Roth Capital Partners, LLC (“ROTH”), www.roth.com, will host its 36th Annual Conference on March 17-19, 2024, at The Ritz Carlton, Laguna Niguel, located in Dana Point, CA. The annual ROTH Conference provides an exceptional platform for institutional investors to connect with executive management from […]
ROTH MKM to Host 35th Annual Roth Conference from March 12-14 in Dana Point, California
March 6, 2023
NEWPORT BEACH, Calif., March 06, 2023 (GLOBE NEWSWIRE) — via InvestorWire — ROTH MKM (“Roth”), www.roth.com, will host its 35th Annual Conference on March 12-14, 2023, at The Ritz Carlton, Laguna Niguel, located in Dana Point, CA. The annual Roth Conference offers companies an extraordinary platform for relationship building with both existing and prospective institutional investors. […]